Sign InBreakout Stocks of Week 19 @ OTCMKTS
NASDAQ was up last week (week 18) by 1.12% ending at 25,114.44 points after gaining 277.84 points during the week. Our system has detected some possible breakout stocks for the following week and these should be on your watchlist. These are the stocks that are bouncing up with good increase in volume and are likely to do good in short term. One of these stocks are Relmada Therapeutics, Inc. OTCMKTS:RLMD. This stock has had a buy signal since Feb 18, 2026 when the price was $4.08 and is so far up 87.25% to $7.64. Some other companies are on our watchlist to, among these are which all got a breakout pattern emerging.
| Date | Company | Price | Week 19 |
|---|---|---|---|
| Relmada Therapeutics, Inc. | $7.64 | $7.32 | -4.19% |
The Relmada Therapeutics, Inc. stock price gained 1.60% on the last trading day (Friday, 1st May 2026), rising from $7.52 to $7.64. It has now gained 4 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 5.12% from a day low at $7.42 to a day high of $7.80. The price has been going up and down for this period, and there has been a 2.14% gain for the last 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 36 thousand more shares were traded than the day before. In total, 942 thousand shares were bought and sold for approximately $7.20 million.
On Mar 24, 2026, it was reported that Piper Sandler gave RLMD a "Overweight" grade with a "initialise" action.
Relmada Therapeutics, Inc. holds several positive signals and is within a strong rising trend. As the old saying says, "Let the trend be your friend.'". We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months.
About Relmada Therapeutics, Inc.:
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Despite these candidates are looking good from a technical perspective they may not perform as expected. You should always be cautious when trading and base your decisions on more than one source of information. This does not constitute an offer or recommendation to buy or sell securities.
GOLDEN STAR
| Ticker | Change | Signal Date |
|---|---|---|
RUN
$12.83
|
4.09% | May 06 |
GLBE
$31.61
|
1.65% | May 05 |
SAP
$172.39
|
7.18% | May 05 |
FIZZ
$34.11
|
7.04% | May 01 |
ADBE
$243.57
|
3.23% | Apr 29 |
